Professor of Otolaryngology, University Pittsburgh
Otolaryngology (ENT)
Dr. Jennifer R. Grandis, MD
|
|
Give Review
Jennifer Grandis works in the field of Otolaryngology (ENT). She went to University of Pittsburgh School of Medicine. She has 5 awards "America's Top Doctors", "America's Top Doctors for Cancer", "Pittsburgh Magazine", "Elected Member" and "Fellow (FACS)". Jennifer R. Grandis is a published doctor as well. She has 97 publications published. The latest was: Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. Jennifer Grandis accepts all Medicare patients.
Publications
- Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.
- Oral Cancer Chemoprevention-The End of EPOC, the Beginning of an Epoch of Molecular Selection.
- Therapeutic insights from genomic studies of Head and neck squamous cell carcinomas.
- JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth.
- HER2 as a therapeutic target in Head and neck squamous cell carcinoma.
- Incidence of Head and neck squamous cell carcinoma among subjects at high risk of lung cancer: Results from the Pittsburgh Lung Screening Study.
- Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for Head and neck squamous cell carcinoma.
- Characterization of HPV and host genome interactions in primary Head and neck cancers.
- Receptor-type protein tyrosine phosphatases in cancer.
- Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative On...
- Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p Loss.
- 2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway.
- Genomic analysis of Head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.
- Caspase-8 mutations in Head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth.
- Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable Head and neck cancer.
- Chemoprevention of Head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
- Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in Head and neck cancer.
- Identification of Mutations in the PYRIN-Containing NLR Genes (NLRP) in Head and Neck Squamous Cell Carcinoma.
- Systemic Administration of a Cyclic STAT3 Decoy Oligonucleotide Inhibits Tumor Growth Without Inducing Toxicological Effects.
- Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients.
- Collagen type XI α1 facilitates Head and neck squamous cell cancer growth and invasion.
- Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in Head and neck squamous cell carcinoma cells.
- Integration of molecular targeted therapy with radiation in Head and neck cancer.
- High-Content pSTAT3/1 Imaging Assays to Screen for Selective Inhibitors of STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers.
- Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.
- Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma.
- Childhood passive smoke exposure is associated with adult Head and neck cancer.
- Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.
- Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: Association with Head and neck squamous cell carcinoma.
- Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of Head and neck carcinoma.
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the Head and neck.
- c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met.
- The Fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma.
- Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models.
- Molecular Pathways: Context-Dependent ApproAches to Notch Targeting as Cancer Therapy.
- Nucleic acid-based approAches to STAT inhibition.
- The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
- Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer.
- Preclinical modeling of EGFR inhibitor resistance in Head and neck cancer.
- Screening for Head and neck cancer in liver transplant candidates: A review of 11 years of experience at the University of Pittsburgh.
- Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the Head and neck are treatment dependent.
- Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
- Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced Head and neck cancer.
- Assembly And Initial Characterization Of A Panel Of 85 Genomically Validated Cell Lines From Diverse Head And Neck Tumor Sites.
- Targeting mesenchymal exaptation to mitigate tumor growth.
- The mutational landscape of Head and neck squamous cell carcinoma.
- Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
- Female hormonal and reproductive factors and Head and neck squamous cell carcinoma risk.
- XPF expression correlates with clinical outcome in squamous cell carcinoma of the Head and neck.
- Targeting GPCR-mediated p70S6K activity may improve Head and neck cancer response to cetuximab.
- Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in Head and neck carcinoma cells.
- MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the Head and neck.
- Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.
- Response to combined molecular targeting: defining the role of P-STAT3.
- Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.
- STAT3 signaling: anticancer strategies and challenges.
- Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.
- Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced...
- New advances in molecular approAches to head and neck squamous cell carcinoma.
- Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the Head and neck.
- The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic B...
- Human papillomavirus and Head and neck cancer.
- Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.
- Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR.
- Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in Head and neck cancer.
- Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
- New strategies in Head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.
- The impact of health insurance status on the survival of patients with Head and neck cancer.
- Management of patients treated with chemoradiotherapy for Head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience.
- The molecular pathogenesis of Head and neck cancer.
- The current state of Head and neck cancer gene therapy.
- Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the Head and neck: results of a phase I dose-escalation trial.
- Cross-talk between estrogen receptor and epidermal growth factor receptor in Head and neck squamous cell carcinoma.
- STAT3 activation contributes directly to Epstein-Barr virus-Mediated invasiveness of nasopharyngeal cancer cells in vitro.
- Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription...
- HGF and c-Met participate in paracrine tumorigenic pathways in Head and neck squamous cell cancer.
- ABT-737 synergizes with chemotherapy to kill Head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
- Targeting angiogenesis from premalignancy to metastases.
- Intratumoral epidermal growth factor receptor antisense DNA therapy in Head and neck cancer: first human application and potential antitumor mechanisms.
- ErbB receptors in the biology and pathology of the aerodigestive tract.
- Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in Head and neck squamous cancer cells.
- Molecular target approAches in head and neck cancer: epidermal growth factor receptor and beyond.
- Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epiderm...
- Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in Head and neck squamous cell carcinomas.
- Genetic screening for oral human papillomavirus infections and cancers of the Head and neck.
- Resveratrol causes COX-2- and p53-dependent apoptosis in Head and neck squamous cell cancer cells.
- Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of Head and neck squamous cell carcinoma.
- Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated Head and neck squamous cell carcinoma invasion.
- Targeting epidermal growth factor receptor and SRC pathways in Head and neck cancer.
- Introduction: Head and neck cancer.
- Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.
- Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell ca...
- Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of Head and neck squamous cell carcinoma cells.
- Emerging perspectives in epidermal growth factor receptor targeting in Head and neck cancer.
- Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in...
Schools
University of Pittsburgh Main Campus
University Of Pittsburgh
Procedures Preformed
- Diagnostic Nasal and-or Sinus Endoscopy
- Lymph Node Biopsy or Excision
Conditions Treated
- Allergic Rhinitis
- Chronic Sinusitis
- Chronic Tonsillitis
- Conductive Hearing Loss
- View All
Doctors Specialties
- Ear, Nose, and Throat
- Otolaryngology (ENT)
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Pittsburgh Magazine
- Elected Member
- Fellow (FACS)
Education
-
University of Pittsburgh Medical Center -
University of Pittsburgh School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1497729735 | |
| NPPES Provider LastName | GRANDIS | |
| NPPES Provider FirstName | JENNIFER | |
| NPPES Provider ZIPCode | 152132546 | |
| NPPES Provider State | PA | |
| Specialty Description | Otolaryngology | |
| Total Claim Count | 230.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497729735 |
| Last Name Of The Provider | GRANDIS |
| First Name Of The Provider | JENNIFER |
| View All |
Similar Doctors
|
|
Dr. Cuneyt M. Alper, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Seungwon Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David E. Eibling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sidney N. Busis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melonie A. Nance, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Duane G. Martin, MD |
|
|
Dr. Summit B. Kundaria, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Beverly Richert, CRNP |